Trading of Co-Diagnostics was halted at 09:35 AM EST due to "LULD Pause". Co-Diagnostics (CODX) FDA Approvals $7.27 -1.26 (-14.78%) As of 10:56 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Co-Diagnostics' Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by Co-Diagnostics (CODX). Over the past two years, Co-Diagnostics has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as Co-Dx™. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. Co-Dx™ FDA Regulatory Events Co-Dx™ is a drug developed by Co-Diagnostics for the following indication: PCR COVID-19 test instrument. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Provided Update - June 2,2026Provided Update Drug: Co-Dx™Announced Date: June 2, 2026Indication: PCR COVID-19 test instrument AnnouncementCo-Diagnostics, Inc. announced continued progress in its Ebola PCR development program with joint venture CoSara Diagnostics Pvt. Ltd. ("CoSara" or the "JV").AI SummaryCo-Diagnostics, Inc. said its joint venture, CoSara Diagnostics Pvt. Ltd., is making steady progress on an Ebola PCR development program. The company is working on a dual-assay strategy that could help both outbreak response and ongoing surveillance in affected regions. One possible test would use blood samples, which could expand the capabilities of Co-Dx’s PCR point-of-care platform. Co-Diagnostics said this approach may offer more flexibility for public health response efforts, including support for potential non-governmental organization partners. The project is still in development and will need validation, regulatory review, and future deployment steps before it can be used. The company said the effort is meant to improve readiness for Ebola response in areas that may need fast and reliable testing.Read Announcement Co-Diagnostics FDA Events - Frequently Asked Questions Has Co-Diagnostics received FDA approval? As of now, Co-Diagnostics (CODX) has not received any FDA approvals for its therapy in the last two years. What drugs has Co-Diagnostics submitted to the FDA? In the past two years, Co-Diagnostics (CODX) has reported FDA regulatory activity for Co-Dx™. What is the most recent FDA event for Co-Diagnostics? The most recent FDA-related event for Co-Diagnostics occurred on June 2, 2026, involving Co-Dx™. The update was categorized as "Provided Update," with the company reporting: "Co-Diagnostics, Inc. announced continued progress in its Ebola PCR development program with joint venture CoSara Diagnostics Pvt. Ltd. ("CoSara" or the "JV")." What conditions do Co-Diagnostics' current drugs treat? Currently, Co-Diagnostics has one therapy (Co-Dx™) targeting the following condition: PCR COVID-19 test instrument. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events Evogene FDA EventsRezolute FDA EventsVera Therapeutics FDA EventsActuate Therapeutics FDA EventsAprea Therapeutics FDA EventsAura Biosciences FDA EventsBriacell Therap FDA EventsCelcuity FDA EventsCellectar Biosciences FDA EventsCitius Pharmaceuticals FDA EventsCytokinetics FDA EventsAlpha Tau Medical FDA EventsEnlivex Therapeutics FDA EventsGreenwich LifeSciences FDA EventsIDEAYA Biosciences FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies Avita Medical FDA Events Microbot Medical FDA Events Nyxoah FDA Events Inovio Pharmaceuticals FDA Events PolyPid FDA Events electroCore FDA Events Envoy Medical FDA Events Plus Therapeutics FDA Events NeuroOne Medical Technologies FDA Events Cytosorbents FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare and Medical Stocks FDA progress for NASDAQ:CODX last updated on 6/2/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersA gold storm is coming – are you ready?The U.S. Treasury Secretary is betting big on gold - and the world's most successful investors are following s...Traders Agency | SponsoredYour Retirement Could Flourish Under Trump's Economic BoomA quiet financial shift is underway - and retirees relying on traditional 401(k)s, IRAs, and TSPs may be most ...American Hartford Gold | SponsoredHow to claim a stake in SpaceX before the June 12 IPOSpaceX is expected to go public on June 12 - and for the first time, everyday investors may have a way in befo...Brownstone Research | SponsoredWhat really happened in Beijing?Trump just returned from Beijing with the most powerful business delegation in American history - Elon Musk, J...Porter & Company | SponsoredElon Now Pays 15X More Than Your BankElon Musk's new bank is offering 6% interest per year - that's 15 times the national average of 0.4% that most...InvestorPlace | SponsoredPresident Trump just sparked a stock market MELT UPThe real reason Musk, Huang, Cook, and Fink just flew to Beijing Last week, the CEOs of Nvidia, Apple, Spac...Stansberry Research | SponsoredGold hit $4,500 - but these miners haven't caught up yet$9 trillion in U.S. debt must be refinanced in 2026 - at current rates - while the largest foreign buyers of T...Golden Portfolio | SponsoredWhere did Vanguard quietly put $101 billion?Vanguard holds $101 billion in three AI companies most investors have never heard of. BlackRock holds $82 bill...Eagle Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Co-Diagnostics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Co-Diagnostics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Provided Update - June 2,2026Provided Update Drug: Co-Dx™Announced Date: June 2, 2026Indication: PCR COVID-19 test instrument AnnouncementCo-Diagnostics, Inc. announced continued progress in its Ebola PCR development program with joint venture CoSara Diagnostics Pvt. Ltd. ("CoSara" or the "JV").AI SummaryCo-Diagnostics, Inc. said its joint venture, CoSara Diagnostics Pvt. Ltd., is making steady progress on an Ebola PCR development program. The company is working on a dual-assay strategy that could help both outbreak response and ongoing surveillance in affected regions. One possible test would use blood samples, which could expand the capabilities of Co-Dx’s PCR point-of-care platform. Co-Diagnostics said this approach may offer more flexibility for public health response efforts, including support for potential non-governmental organization partners. The project is still in development and will need validation, regulatory review, and future deployment steps before it can be used. The company said the effort is meant to improve readiness for Ebola response in areas that may need fast and reliable testing.Read Announcement
